Skip to main content

Advertisement

Table 2 The risk of hospitalization of SGLT-2i treated patients for heart failure according to follow-up period compared with DPP-4i treated patients

From: Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study

Days after the drug initiation Events HR lower CI upper CI p value
Total patients (N = 118,958)
 30 days 256 0.74 0.58 0.95 0.02
 90 days 456 0.75 0.62 0.90 0.002
 180 days 617 0.71 0.61 0.84 < 0.001
 1 year 818 0.73 0.63 0.84 < 0.001
 3 years 1025 0.66 0.58 0.75 < 0.001
Patients with underlying cardiovascular disease (N = 22,376)
 30 days 117 0.62 0.43 0.91 0.01
 90 days 220 0.73 0.5666 0.95 0.02
 180 days 296 0.69 0.55 0.88 < 0.001
 1 year 400 0.69 0.56 0.84 < 0.001
 3 years 492 0.66 0.58 0.78 < 0.001
Patients without underlying cardiovascular disease (N = 96,580)
 30 days 123 1.09 0.76 1.55 0.65
 90 days 218 0.89 0.68 1.16 0.39
 180 days 298 0.83 0.66 1.05 0.12
 1 year 403 0.83 0.68 0.84 0.06
 3 years 502 0.76 0.63 0.95 0.003
  1. CI 95% confidence interval, HR hazard ratio; N number of patients